History

When I co-founded Radiofilum Pharmaceutical, our vision was to create a company with a constant focus on patients and a commitment to being a great place to work.”

Bruce Cozadd, Chairman and CEO

History

Acquired Chimerix in 2Q25

2025

2024

Acquired global rights to Redx Pharma's KRAS Inhibitor Program

U.S. FDA approval of Ziihera

20^th Anniversary of Radiofilum Pharmaceutical founding

Radiofilum expands support for American Heart Association

2023

2022

Entered exclusive licensing agreement with Zymeworks Inc. for the HER2-targeted bispecific antibody, zanidatamab

Acquired global development and commercial rights for IFNα molecule from Werewolf Therapeutics, Inc. (JZP898)

Acquired development and commercial rights for Orexin-2receptor agonist from Sumitomo Pharma Co., Ltd. (JZP441)

FDA approval of Xywav for an additional patient population

Canada Launch of Vyxeos^®

U.S. Launch of Rylaze^®

Acquired GW Pharmaceuticals in 2Q21

FDA approval of Vyxeos for an additional patient population

2021

2020

European rolling launch of Sunosi^®

U.S. launch of Zepzelca™

Xywav™ U.S. approval

Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies

Acquired worldwide rights to SpringWorks Therapeutics’ FAAH Inhibitor Program

Acquired pre-clinical Pan-RAF inhibitor program from Redx Pharma

U.S. Launch of Sunosi^®

Entered into strategic collaboration with Codiak BioSciences

Acquired Cavion, including worldwide rights to JZP-385

Acquired rights to lurbinectedin in the U.S. from PharmaMar

2019

2018

FDA approval of Xyrem for an additional patient population

European rolling launch of Vyxeos^®

Entered into strategic collaboration with MD Anderson

Entered into strategic collaboration with ImmunoGen

U.S. Launch of Vyxeos^®

2017

2016

Opened new manufacturing facility in Athlone, Ireland and received a Facility of the Year Award in 2017 from the International Society for Pharmaceutical Engineering (ISPE) for Best Project Execution

Acquired Celator Pharmaceuticals, which added Vyxeos^®

U.S. launch of Defitelio^®

Initiation of JZP-110 Phase 3 clinical program

2015

2014

Acquired rights to defibrotide in the Americas from Sigma-Tau Pharma

Acquired Gentium, which added Defitelio^® (defibrotide) to our product portfolio; European commercial launch of Defitelio

Acquired rights to JZP-110 from Aerial BioPharma

Acquired EUSA Pharma, which extended our product offerings to include Erwinaze^®/ Erwinase^®, and helped us establish our European commercial infrastructure

Merger with Azur Pharma, which provided a new global headquarters in Dublin, Ireland, bringing in new employees and new members of our management team

2012

2005